tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kevin Kedra, 6 are a HOLD (37.5%), 2 are a SELL (12.5%), 8 are a BUY (50%).
Analyst Kevin Kedra, carries an average stock price target met ratio of 91.67% that have a potential upside of 72.4% achieved within 787 days. Previously, Kevin Kedra worked at GABELLI.
Kevin Kedra’s has documented 35 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ELAN, Elanco Animal Health at 17-Jun-2021.
Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Jan-2021
$3.1
$0.55 (21.57%)
$2.3
Buy Since 16-Jul-2024
$6
$3.45 (135.29%)
$6
Hold Since 07-Mar-2023
$0.85
$-1.7 (-66.67%)
$3
Buy Since 12-Aug-2022
$10
Buy Since 09-Nov-2015
$8
$6.28 (365.12%)
What Year was the first public recommendation made by Kevin Kedra?
